S
Serge Muyldermans
Researcher at Vrije Universiteit Brussel
Publications - 323
Citations - 30516
Serge Muyldermans is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Single-domain antibody & Antibody. The author has an hindex of 80, co-authored 305 publications receiving 26561 citations. Previous affiliations of Serge Muyldermans include Dalian University of Technology & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.
Amanda Sparkes,Amanda Sparkes,Patrick De Baetselier,Patrick De Baetselier,Lea Brys,Lea Brys,Inês Cabrito,Inês Cabrito,Yann G.-J. Sterckx,Steve Schoonooghe,Steve Schoonooghe,Serge Muyldermans,Geert Raes,Geert Raes,Richard Bucala,Peter Vanlandschoot,Jo A. Van Ginderachter,Jo A. Van Ginderachter,Benoit Stijlemans,Benoit Stijlemans +19 more
TL;DR: Nbs, with their structural and pharmacologic advantages over currently available inhibitors, may be an effective, novel approach to interfere with the action of MIF in septic shock and other conditions of inflammatory endorgan damage.
Patent
Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains
Hamers R,Serge Muyldermans +1 more
TL;DR: In this article, the use of variable fragments of immunoglobulin which are by nature devoid of light chains was proposed. But these fragments were nevertheless capable of exhibiting a recognition and binding activity toward specific antigens.
Journal ArticleDOI
Application of Single-Domain Antibodies ("Nanobodies") to Laboratory Diagnosis.
TL;DR: Single-domain antibodies as discussed by the authors are a relatively new class of diagnostic probes that originated serendipitously during the assay of camel serum and are very stable and heat-resistant, and hence do not require cold storage.
Journal ArticleDOI
Nanobodies as novel therapeutic agents in envenomation.
Ehsan Alirahimi,Fatemeh Kazemi-Lomedasht,Delavar Shahbazzadeh,Mahdi Habibi-Anbouhi,Mohammad Hosseininejad Chafi,Nazli Sotoudeh,Hajarossadat Ghaderi,Serge Muyldermans,Mahdi Behdani +8 more
TL;DR: Nanobodies as a venom-neutralizing agent can be considered as a valuable and promising candidate in envenomation therapy and in vivo research activities that investigate the performance of recombinant, monoclonal nanobodies in venom neutralization are focused on.
Journal ArticleDOI
A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation
Najmeh Yardehnavi,Mahdi Behdani,Kamran Pooshang Bagheri,Amir Mahmoodzadeh,Hossein Khanahmad,Delavar Shahbazzadeh,Mahdi Habibi-Anbouhi,Gholamreza Hassanzadeh Ghassabeh,Serge Muyldermans +8 more
TL;DR: A functional recombinant Nb (referred to as F7Nb) had good antihemolytic and antidermonecrotic effects against HNc in all tested mice and is a potential leading novel candidate for treating H. lepturus scorpionism in the near future.